Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (490)	12/23/1999 7:27:00 AM
From: OldAIMGuy	Respond to of 1154

Hi LL, The management of GENE has been able to run their business for over a decade with only one serious deficit period in the '80s when a Swiss pharm. pulled out of a collaborations. They're good scientists and run a pretty tight ship from a financial point of view. The most recent news shows that GENE is now able to sell their science where in years past they were struggling to get collaborations. These latest deals show strength in forming the collaborations. Being good managers, the deals should be profitable. Best regards, Tom